Disclosed are compounds which have been identified as inhibitors of phosphate transport. Many of the compounds are represented by Structural Formula (I):
Ar
1
—W—X—Y—Ar
2
;
or a pharmaceutically acceptable salt thereof. Ar
1
and Ar
2
are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C1-C3 substituted or unsubstituted alkylene group. X is a heteroatom-containing functional group, an aromatic heterocyclic group, substituted aromatic heterocyclic group, non-aromatic heterocyclic group, substituted non-aromatic heterocyclic group, an olefin group or a substituted olefin group. Also disclosed are methods of treating a subject with a disease associated with hyperphosphatemia, as well as a disease mediated by phosphate-transport function. The methods comprise the step of administering an effective amount of the one of the compounds described above.
Effective Synthesis of<i>N</i>-Arylformamide from α-Halo-<i>N</i>-arylacetamides
作者:Kun-Heng Chiang、Shi-Han Lu、Wan-Ping Yen、Naoto Uramaru、Wei-Siou Tseng、Te-Wei Chang、Fung Fuh Wong
DOI:10.1002/hc.21321
日期:2016.7
A convenient synthetic method for N-arylformamide derivatives was successfully developed by reacting α-iodo-N-arylacetamides with formamide. This method was applicable to α-iodo-N-arylacetamide substrates bearing electron-donating or electron-withdrawing groups, N-(benzo[d][1,3]dioxol-5-yl)-2-iodoacetamide, 2-iodo-N-(pyridin-2-yl)acetamide, and 2-iodo-N-(naphthalen-4-yl)acetamide to give the corresponding